24 February 2016 - In final guidelines, the National Institute for Health and Care Excellence says the drug can be used as a monotherapy to treat adult patients with primary (heterozygous‑familial or non‑familial) hypercholesterolaemia in whom initial statin therapy is contraindicated or not tolerated.

For more details, go to: http://www.pharmatimes.com/Article/16-02-24/NICE_final_nod_for_MSD_s_cholesterol_buster_Ezetrol.aspx